Regencell Bioscience Holdings Limited (RGC) P/B ratio

P/B ratio today
169.0×

Regencell Bioscience Holdings Limited (RGC) trades at 169.0× its book value per share at the end of fiscal 2026. At the end of fiscal 2026 (June 30, 2026) its P/B ratio was 226.2×. Today's figure is 25.3% below the fiscal 2026 year-end. Figures as of 18 Nov 2026, 10:34 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/B ratio today
169.0×
P/B ratio, fiscal 2026
226.2×
Highest on record
226.2×fiscal 2026
Lowest on record
5.3×fiscal 2024
Fiscal years on record
42022–2026

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Regencell Bioscience Holdings Limited P/B ratio, in more detail

Across the 4 fiscal year-ends on record (2022–2026), the highest was 226.2× in fiscal 2026 and the lowest 5.3× in fiscal 2024. Today's P/B ratio is higher than at 75% of the 4 fiscal year-ends on record; their median is 25.4×.

History · 4 fiscal years

P/B ratio at each fiscal year-end

The last point is today's figure; the others are fiscal year-ends.

Regencell Bioscience Holdings Limited P/B ratio, year by year

Regencell Bioscience Holdings Limited (RGC) P/B ratio by fiscal year
Fiscal yearP/B ratioChangeYear endedShare price at year-endBook value per share
Today169.0×—$4.55—
2026226.2×—$6.09$0.03
20245.3× 78.7% down$0.09$0.02
202324.9× 4.0% down$0.61$0.02
202226.0×—$0.91$0.04
2021———-$0.01
2020———-$0.01
2019———-$1,209,553.29

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B.

How to read it

It compares the price with the accounting value of what the company owns net of what it owes, and matters most for banks, insurers and other balance-sheet businesses.

More on RGC

Regencell Bioscience Holdings Limited, figure by figure

Regencell Bioscience Holdings Limited (RGC) overview: price, valuation and scorecard

Regencell Bioscience Holdings Limited P/B ratio: questions and answers

What is Regencell Bioscience Holdings Limited's P/B ratio?

Regencell Bioscience Holdings Limited (RGC) trades at 169.0× its book value per share at the end of fiscal 2026. At the end of fiscal 2026 (June 30, 2026) its P/B ratio was 226.2×.

Is Regencell Bioscience Holdings Limited's P/B ratio high or low compared with its own history?

Today's P/B ratio is higher than at 75% of the 4 fiscal year-ends on record; their median is 25.4×.

What are the highest and lowest P/B ratio figures on record for Regencell Bioscience Holdings Limited?

Across the 4 fiscal year-ends on record (2022–2026), the highest was 226.2× in fiscal 2026 and the lowest 5.3× in fiscal 2024.

How is Regencell Bioscience Holdings Limited's P/B ratio calculated?

The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B. For Regencell Bioscience Holdings Limited it is on record here for 4 fiscal years, 2022 to 2026.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Regencell Bioscience Holdings Limited (RGC) P/B ratio”, data as of 18 November 2026. https://funkfolio.com/stock/RGC/pb-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.